WSL
ALPN

Western Standard LLC’s Alpine Immune Sciences Inc ALPN Stock Holding History

Western Standard LLC’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50,328
Closed -$428K – 39
2022
Q2 		$428K Buy
+50,328
New +$434K 0.32% 35

Other funds holding ALPN

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Western Standard LLC's ALPN Position: Q3 2022 in Review

Western Standard LLC sold out of Alpine Immune Sciences Inc (ALPN) in Q3 2022, closing a stake of 50,328 shares — an estimated $428K sold.

Western Standard LLC first reported a position in ALPN in Q2 2022 and held it in 1 quarter. The position peaked at $428K in Q2 2022. 70 funds tracked by Wall St. Rank hold ALPN as of Q3 2022.

  • Western Standard LLC reported no remaining Alpine Immune Sciences Inc position as of Q3 2022 after selling out during the quarter.
  • Western Standard LLC sold 50,328 Alpine Immune Sciences Inc shares in Q3 2022, an estimated $428K.
  • Western Standard LLC first reported a position in Alpine Immune Sciences Inc in Q2 2022 and held it in 1 quarter.
  • Western Standard LLC's Alpine Immune Sciences Inc position peaked at $428K in Q2 2022.
  • 70 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q3 2022.

Based on Western Standard LLC's 13F filing for Q3 2022, filed 14 Nov 2022.